Related references
Note: Only part of the references are listed.Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open- label, multicenter phase 2 basket study
Lingfang Xia et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer The APPROVE Randomized Clinical Trial
Tiantian Wang et al.
JAMA ONCOLOGY (2022)
A Comparison of Chemotherapy Used with and without Apatinib for Patients with Ovarian Carcinoma Who Progressed after Standard Regimens: A Systematic Review and Meta-Analysis
Chao Hou et al.
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Ovarian Cancer, Version 2.2020
Deborah K. Armstrong et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Programmed death ligand-1 regulates angiogenesis and metastasis by participating in the c-JUN/VEGFR2 signaling axis in ovarian cancer
Yufei Yang et al.
CANCER COMMUNICATIONS (2021)
Advances in the treatment of platinum resistant epithelial ovarian cancer: an update on standard and experimental therapies
Shuk on Annie Leung et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)
The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer
Masayuki Sekine et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2021)
Evaluation of safety and efficacy of apatinib combination with chemotherapy for ovarian cancer treatment: a systematic review and meta-analysis
Jing Qi et al.
ANNALS OF PALLIATIVE MEDICINE (2021)
Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review
Rebecca Arend et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2020)
Therapeutic potentials of Apatinib in cancer treatment: Possible mechanisms and clinical relevance
Nazila Fathi Maroufi et al.
LIFE SCIENCES (2020)
Recurrent Treatment in Ovarian Cancer Patients: What Are the Best Regimens and the Order They Should Be Given?
Joanna Glajzer et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2020)
REBECA trial: a new piece of the evidence for bevacizumab in platinum-resistant recurrent ovarian cancer
Daniele Lavacchi et al.
TRANSLATIONAL CANCER RESEARCH (2020)
Efficacy and safety of low-dose apatinib in ovarian cancer patients with platinum-resistance or platinum-refractoriness: A single-center retrospective study
Wei Chen et al.
CANCER MEDICINE (2020)
Epidemiology of ovarian cancer
Patricia Gaona-Luviano et al.
CHINESE CLINICAL ONCOLOGY (2020)
Adverse events and management of apatinib in patients with advanced or metastatic cancers: A review
F. Shao et al.
NEOPLASMA (2020)
Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Ovarian cancer: Current status and strategies for improving therapeutic outcomes
Ashwin Chandra et al.
CANCER MEDICINE (2019)
Efficacy And Safety Of Apatinib Treatment In Platinum-Resistant Recurrent Epithelial Ovarian Cancer: A Real World Study
Jindi Zhang et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2019)
Apatinib, a novel tyrosine kinase inhibitor, suppresses tumor growth in cervical cancer and synergizes with Paclitaxel
Haifeng Qiu et al.
CELL CYCLE (2018)
Platinum-resistant recurrent ovarian cancer with long survival on bevacizumab and gemcitabine
Shinichi Komiyama et al.
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH (2018)
Multiline treatment combining apatinib with toptecan for platinum-resistant recurrent ovarian cancer patients: a report of three cases
Yuan Cheng et al.
ONCOTARGETS AND THERAPY (2018)
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO)
A. Lortholary et al.
ANNALS OF ONCOLOGY (2012)
YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo
Shu Tian et al.
CANCER SCIENCE (2011)
Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer
T. Le et al.
GYNECOLOGIC ONCOLOGY (2006)